XNAS
ROIV
Market cap24bUSD
Oct 08, Last price
34.21USD
1D
-1.55%
1Q
-4.89%
IPO
228.94%
Name
Roivant Sciences Ltd
Chart & performance
P/E
—
P/S
2,991.95
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.26%
Rev. gr., 5y
-19.07%
Revenues
8m
-71.57%
Net income
-300m
L+74.30%
CFO
-750m
L-10.61%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2020 and headquartered in Menlo Park, California, Montes Archimedes Acquisition Corp. is dedicated to completing business combinations. These combinations encompass a variety of structures, such as mergers, capital stock exchanges, asset acquisitions, stock purchases, or corporate reorganizations, with other enterprises.
Related entities
Subsidiaries
Roivant Sciences GmbH
Key people
Richard Pulik
Chief Financial Officer · since 2021
President and Vant Chairman · since 2025
President and Immunovant Chief Executive Officer · since 2025
Jennifer Humes
Chief Accounting Officer · since 2025
Matthew Gline
Chief Executive Officer, Director · since 2021
Mayukh Sukhatme
President, Chief Investment Officer, Director · since 2023
Independent Director · since 2022
Independent Director · since 2023
Daniel Gold
Independent Director · since 2020
Keith Manchester
Independent Director · since 2014
Independent Director · since 2021
Independent Chairman of the Board · since 2023
Legal address
Clarendon House - 2 Church Street
Hamilton HM 11
BM
Hamilton HM 11
BM
Headquarters
7th Floor
50 Broadway
London SW1H 0DB
GB
50 Broadway
London SW1H 0DB
GB
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||